Year: 2023
Type: letter
Abstract: We thank Drs Han and Li for their interesting comment concerning our manuscript1. We agree that our study, as well as those published previously on the same subject, raise important questions concerning cytomegalovirus (CMV) screening. In France, different recommendations exist on the topic, some of which are against (Haute Autorité de Santé and Haut Conseil de la Santé Publique) and some of which are in favor (Collège National des Gynécologues et Obstétriciens Français, Research Group on Infections during Pregnancy and Académie de Médecine) of CMV screening. Therefore, CMV screening is dependent on each practitioner's preference. In France, CMV screening is performed in 50% of all pregnant women. Our study evaluated prevention of viral transmission only and not treatment of CMV-infected fetuses. We agree that continuing the treatment after amniocentesis has not been evaluated to date. Proving the value of this strategy would require a large number of patients and would be a difficult goal to achieve. Our results, as well as those of other studies on the topic of prevention of viral transmission, provide enough data to support the routine use of valacyclovir for this indication. Another randomized study would be unethical because it would lead to some patients missing the chance of receiving treatment to prevent fetal infection and its associated sequelae. The benefit of treating an infected fetus is another issue, which was not evaluated in our study. The next step should be the evaluation of the economic acceptability of a strategy involving screening for CMV and valacyclovir treatment. Future studies should also focus on improving diagnosis and management of non-primary infections. In our opinion, if not systematically performed, CMV screening should be systematically proposed, especially to patients at high risk of seroconversion. Not using valacyclovir in the prevention of maternal–fetal transmission would be a lost opportunity. Couples deserve to be informed about the available management strategy for CMV, and valacyclovir is mandatory to prevent viral transmission to the fetus, especially during the first trimester.
DOI: 10.1002/uog.26124
Authors: O. Picone, the coauthors
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4313532164
